Alcon Buys Belkin Vision for up to $385M

Alcon has acquired Belkin Vision, maker of direct selective laser trabeculoplasty (DLST) technology.

The deal has upfront consideration of $81 million, including a cash payment of about $65 million. The transaction also includes potential for up to $385 million in payments, depending on sales-based milestones.

The deal for Belkin fortifies Alcon’s portfolio with a first-line therapy. Alcon also boasts treatments for glaucoma, like the Hydrus microstent and pharmaceutical drops available in the U.S.

Selective laser trabeculoplasty (SLT) is a primary treatment for open angle glaucoma (OAG) and ocular hypertension (OHT). DSLT can effectively lower intraocular pressure (IOP). DSLT delivers laser energy to the trabecular meshwork as well, but adds eye-tracking tech for accurate, automated treatment delivery through the limbus.

DSLT tech is approved in the EU and UK. The device earned U.S. Food and Drug Administration (FDA) 510(k) clearance but isn’t yet available in the U.S. Alcon hopes to make DSLT available to to U.S. physicians by the end of 2024.

The company is also integrating the technology into its Alcon Vision Suite.

“As a therapy with significant advantages for the patient and practice, we believe our newly acquired DSLT technology is uniquely positioned to accelerate the evolution toward first-line use of SLT in the glaucoma treatment paradigm,” said Sean Clark, president, Global Surgical Franchise, Alcon. “We look forward to broadening access to this exciting technology in the future as we continue to address solutions for unmet needs in glaucoma.”